To explore the potential of CX3CL1 as a prognostic indicator in clinical samples and validate its correlation with Treg infiltration, we conducted multiplex immunofluorescence (mIHC) staining of a tissue microarray containing 100 CRC tissue samples with antibodies against CX3CL1, CD4, CD25, and PANCK (a tumor cell marker). The gene discussed is CX3CL1; the disease is neoplasm.